Insider Transactions in Q2 2023 at Revance Therapeutics, Inc. (RVNC)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Mark J Foley CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.11%
|
$15,000
$15.61 P/Share
|
|
Jun 30
2023
|
Dustin S Sjuts President |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.67%
|
$15,000
$15.61 P/Share
|
|
Jun 30
2023
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
769
+0.93%
|
$11,535
$15.61 P/Share
|
|
Jun 15
2023
|
Carey O Connor Kolaja Director |
SELL
Open market or private sale
|
Direct |
2,500
-13.12%
|
$70,000
$28.24 P/Share
|
|
Jun 15
2023
|
Carey O Connor Kolaja Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+11.6%
|
$45,000
$18.12 P/Share
|
|
Jun 09
2023
|
Mark J Foley CEO |
SELL
Open market or private sale
|
Direct |
31,279
-3.39%
|
$938,370
$30.72 P/Share
|
|
Jun 09
2023
|
Dustin S Sjuts President |
SELL
Open market or private sale
|
Direct |
5,000
-3.28%
|
$150,000
$30.82 P/Share
|
|
Jun 02
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
500
-0.61%
|
$15,500
$31.0 P/Share
|
|
Jun 01
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
2,701
-3.21%
|
$81,030
$30.57 P/Share
|
|
May 15
2023
|
Dwight Moxie CLO & GC |
SELL
Open market or private sale
|
Direct |
21,401
-23.63%
|
$727,634
$34.55 P/Share
|
|
May 15
2023
|
Dustin S Sjuts President |
SELL
Open market or private sale
|
Direct |
21,015
-12.12%
|
$714,510
$34.55 P/Share
|
|
May 15
2023
|
Mark J Foley CEO |
SELL
Open market or private sale
|
Direct |
70,447
-7.09%
|
$2,395,198
$34.55 P/Share
|
|
May 15
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
21,401
-20.3%
|
$727,634
$34.55 P/Share
|
|
May 03
2023
|
Olivia C Ware Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,534
+17.49%
|
-
|
|
May 03
2023
|
Julian S Gangolli Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,534
+10.51%
|
-
|
|
May 03
2023
|
Jill Beraud Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,534
+11.0%
|
-
|
|
May 03
2023
|
Vlad Coric Director |
BUY
Grant, award, or other acquisition
|
Direct |
589
+9.24%
|
-
|
|
May 03
2023
|
Angus C. Russell Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,534
+8.83%
|
-
|
|
May 03
2023
|
Carey O Connor Kolaja Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,534
+17.59%
|
-
|
|
May 03
2023
|
Chris Nolet Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,534
+11.0%
|
-
|
|
May 01
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
3,201
-4.83%
|
$99,231
$31.7 P/Share
|
|
Apr 03
2023
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
3,201
-4.61%
|
$102,432
$32.15 P/Share
|